

16 October 2023

DRUG USAGE IN OPHTHALMOLOGY

1. For the 4 months from May to August 2023, how many patients received the following intra-vitreous treatments for any eye condition:

Aflibercept	5910
Bevacizumab	4
Brolucizumab	0
Dexamethasone	30
Faricimab	8
Ranibizumab – Lucentis	1341
Ranibizumab – Ongavia	0

2. For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

Aflibercept	88
Bevacizumab	0
Brolucizumab	0
Dexamethasone	15
Faricimab	8
Ranibizumab – Lucentis	0
Ranibizumab – Ongavia	0